Loading…
Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt
Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other ex...
Saved in:
Published in: | Clinical and translational medicine 2022-09, Vol.12 (9), p.e1041-n/a |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | n/a |
container_issue | 9 |
container_start_page | e1041 |
container_title | Clinical and translational medicine |
container_volume | 12 |
creator | Agarwal, Sakshi Kaur, Simrandeep Asuru, Tejeswara Rao Joshi, Garima Shrimali, Nishith M Singh, Anamika Singh, Oinam Ningthemmani Srivastva, Puneet Shrivastava, Tripti Vrati, Sudhanshu Surjit, Milan Guchhait, Prasenjit |
description | Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19. |
doi_str_mv | 10.1002/ctm2.1041 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_773281bd149944569fc950ff1820b199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_773281bd149944569fc950ff1820b199</doaj_id><sourcerecordid>2715792819</sourcerecordid><originalsourceid>FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773</originalsourceid><addsrcrecordid>eNpdks9u1DAQxiMEolXpgTewxIXLUo8dJ_EFabX8q1RUiRaulpOMs9564yV2QHvroQ_AM_Ik2GxBFF88-ubzzzOjKYrnQF8Bpeysi1uWohIeFceMUlgAZ9Xjf-Kj4jSEDU2nKaWs2dPiiFfAAGp5XNy9sRj1tCfa7db65-2PG4x-cHPSdERix7VtbQzkavnpiqz8l-RgSTXYRetHoseeTBi6GUNWnd5iT9w8DoFEnzPRT0guGQk6zomY37T7P1g7DmS3vInPiidGu4Cn9_dJ8fnd2-vVh8XF5fvz1fJi0XNWwkJ0DVBtgDe9QdELwQ3VnNUSS9HyRlAE0WAFddUzrnuoqDAGKceqpQ3UNT8pzg_c3uuN2k12mzpXXlv1W_DToPQUbedQJTdroO0hjawsRSVNJwU1BhpGW5AysV4fWLu5TU13OMZJuwfQh5nRrtXgvylZNiWrcjEv7wGT_5rmF9XWhg6d0yP6OShWg6hlKiL_9eI_68bP05hGlVwVbVjNeAaeHVzfrcP930qAqrwnKu-JynuiVtcfWQ74L4oosgY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2760827237</pqid></control><display><type>article</type><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><source>Wiley-Blackwell Open Access Collection</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central (PMC)</source><source>Coronavirus Research Database</source><creator>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</creator><creatorcontrib>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</creatorcontrib><description>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</description><identifier>ISSN: 2001-1326</identifier><identifier>EISSN: 2001-1326</identifier><identifier>DOI: 10.1002/ctm2.1041</identifier><identifier>PMID: 36121179</identifier><language>eng</language><publisher>Heidelberg: John Wiley & Sons, Inc</publisher><subject>Aging ; Blood platelets ; Coronaviruses ; COVID-19 ; DNA methylation ; Enzymes ; Heart surgery ; Infections ; Inflammation ; Investigations ; Letter to the Editor ; Lungs ; Pathogenesis ; Proteins ; Severe acute respiratory syndrome coronavirus 2 ; Thrombosis ; Viral infections</subject><ispartof>Clinical and translational medicine, 2022-09, Vol.12 (9), p.e1041-n/a</ispartof><rights>2022 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2760827237/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2760827237?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11541,25731,27901,27902,36989,36990,38493,43871,44566,46027,46451,53766,53768,74155,74869</link.rule.ids></links><search><creatorcontrib>Agarwal, Sakshi</creatorcontrib><creatorcontrib>Kaur, Simrandeep</creatorcontrib><creatorcontrib>Asuru, Tejeswara Rao</creatorcontrib><creatorcontrib>Joshi, Garima</creatorcontrib><creatorcontrib>Shrimali, Nishith M</creatorcontrib><creatorcontrib>Singh, Anamika</creatorcontrib><creatorcontrib>Singh, Oinam Ningthemmani</creatorcontrib><creatorcontrib>Srivastva, Puneet</creatorcontrib><creatorcontrib>Shrivastava, Tripti</creatorcontrib><creatorcontrib>Vrati, Sudhanshu</creatorcontrib><creatorcontrib>Surjit, Milan</creatorcontrib><creatorcontrib>Guchhait, Prasenjit</creatorcontrib><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><title>Clinical and translational medicine</title><description>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</description><subject>Aging</subject><subject>Blood platelets</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>DNA methylation</subject><subject>Enzymes</subject><subject>Heart surgery</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Investigations</subject><subject>Letter to the Editor</subject><subject>Lungs</subject><subject>Pathogenesis</subject><subject>Proteins</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thrombosis</subject><subject>Viral infections</subject><issn>2001-1326</issn><issn>2001-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9u1DAQxiMEolXpgTewxIXLUo8dJ_EFabX8q1RUiRaulpOMs9564yV2QHvroQ_AM_Ik2GxBFF88-ubzzzOjKYrnQF8Bpeysi1uWohIeFceMUlgAZ9Xjf-Kj4jSEDU2nKaWs2dPiiFfAAGp5XNy9sRj1tCfa7db65-2PG4x-cHPSdERix7VtbQzkavnpiqz8l-RgSTXYRetHoseeTBi6GUNWnd5iT9w8DoFEnzPRT0guGQk6zomY37T7P1g7DmS3vInPiidGu4Cn9_dJ8fnd2-vVh8XF5fvz1fJi0XNWwkJ0DVBtgDe9QdELwQ3VnNUSS9HyRlAE0WAFddUzrnuoqDAGKceqpQ3UNT8pzg_c3uuN2k12mzpXXlv1W_DToPQUbedQJTdroO0hjawsRSVNJwU1BhpGW5AysV4fWLu5TU13OMZJuwfQh5nRrtXgvylZNiWrcjEv7wGT_5rmF9XWhg6d0yP6OShWg6hlKiL_9eI_68bP05hGlVwVbVjNeAaeHVzfrcP930qAqrwnKu-JynuiVtcfWQ74L4oosgY</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Agarwal, Sakshi</creator><creator>Kaur, Simrandeep</creator><creator>Asuru, Tejeswara Rao</creator><creator>Joshi, Garima</creator><creator>Shrimali, Nishith M</creator><creator>Singh, Anamika</creator><creator>Singh, Oinam Ningthemmani</creator><creator>Srivastva, Puneet</creator><creator>Shrivastava, Tripti</creator><creator>Vrati, Sudhanshu</creator><creator>Surjit, Milan</creator><creator>Guchhait, Prasenjit</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202209</creationdate><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><author>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aging</topic><topic>Blood platelets</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>DNA methylation</topic><topic>Enzymes</topic><topic>Heart surgery</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Investigations</topic><topic>Letter to the Editor</topic><topic>Lungs</topic><topic>Pathogenesis</topic><topic>Proteins</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thrombosis</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agarwal, Sakshi</creatorcontrib><creatorcontrib>Kaur, Simrandeep</creatorcontrib><creatorcontrib>Asuru, Tejeswara Rao</creatorcontrib><creatorcontrib>Joshi, Garima</creatorcontrib><creatorcontrib>Shrimali, Nishith M</creatorcontrib><creatorcontrib>Singh, Anamika</creatorcontrib><creatorcontrib>Singh, Oinam Ningthemmani</creatorcontrib><creatorcontrib>Srivastva, Puneet</creatorcontrib><creatorcontrib>Shrivastava, Tripti</creatorcontrib><creatorcontrib>Vrati, Sudhanshu</creatorcontrib><creatorcontrib>Surjit, Milan</creatorcontrib><creatorcontrib>Guchhait, Prasenjit</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical and translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agarwal, Sakshi</au><au>Kaur, Simrandeep</au><au>Asuru, Tejeswara Rao</au><au>Joshi, Garima</au><au>Shrimali, Nishith M</au><au>Singh, Anamika</au><au>Singh, Oinam Ningthemmani</au><au>Srivastva, Puneet</au><au>Shrivastava, Tripti</au><au>Vrati, Sudhanshu</au><au>Surjit, Milan</au><au>Guchhait, Prasenjit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</atitle><jtitle>Clinical and translational medicine</jtitle><date>2022-09</date><risdate>2022</risdate><volume>12</volume><issue>9</issue><spage>e1041</spage><epage>n/a</epage><pages>e1041-n/a</pages><issn>2001-1326</issn><eissn>2001-1326</eissn><abstract>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</abstract><cop>Heidelberg</cop><pub>John Wiley & Sons, Inc</pub><pmid>36121179</pmid><doi>10.1002/ctm2.1041</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2001-1326 |
ispartof | Clinical and translational medicine, 2022-09, Vol.12 (9), p.e1041-n/a |
issn | 2001-1326 2001-1326 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_773281bd149944569fc950ff1820b199 |
source | Wiley-Blackwell Open Access Collection; Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central (PMC); Coronavirus Research Database |
subjects | Aging Blood platelets Coronaviruses COVID-19 DNA methylation Enzymes Heart surgery Infections Inflammation Investigations Letter to the Editor Lungs Pathogenesis Proteins Severe acute respiratory syndrome coronavirus 2 Thrombosis Viral infections |
title | Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T14%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dietary%20alpha%E2%80%90ketoglutarate%20inhibits%20SARS%20CoV%E2%80%902%20infection%20and%20rescues%20inflamed%20lungs%20to%20restore%20O2%20saturation%20by%20inhibiting%20pAkt&rft.jtitle=Clinical%20and%20translational%20medicine&rft.au=Agarwal,%20Sakshi&rft.date=2022-09&rft.volume=12&rft.issue=9&rft.spage=e1041&rft.epage=n/a&rft.pages=e1041-n/a&rft.issn=2001-1326&rft.eissn=2001-1326&rft_id=info:doi/10.1002/ctm2.1041&rft_dat=%3Cproquest_doaj_%3E2715792819%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2760827237&rft_id=info:pmid/36121179&rfr_iscdi=true |